Boron Neutron Capture Therapy in Recurrent High-Grade Gliomas: Safety, Efficacy, and Pharmacokinetics From a Multicenter, Dose-Escalation Phase 1 Trial
This study demonstrates the acceptable safety profile of BNCT and suggests potential survival benefits in recurrent high-grade glioma. However, given the limited sample size and follow-up period, extended observation is required to validate long-term efficacy and safety.
Authors
- Gi Taek Yee (ORCID: https://orcid.org/0000-0002-8706-7253)
- Hyo Jung Seo (ORCID: https://orcid.org/0000-0002-3133-2177)
- Yoo Heon
- Kawngwoo Park (ORCID: https://orcid.org/0000-0002-6568-1009)
- Seunggyun Ha (ORCID: https://orcid.org/0000-0003-2016-1373)
- Woohyoung Kim (ORCID: https://orcid.org/0000-0002-1323-8443)
- Dong-Won Shin (ORCID: https://orcid.org/0000-0002-8163-3357)
- Stephen Ahn (ORCID: https://orcid.org/0000-0002-6854-1597)
- Jin-Ho Song (ORCID: https://orcid.org/0000-0001-5331-7560)
- Hyun Ju Kim (ORCID: https://orcid.org/0000-0002-4406-7552)
- Sung Uk Lee (ORCID: https://orcid.org/0000-0003-2213-706X)
- Jungyu Yi
- H.E. Lim
- Kwan Cho
- Jae-Sung Park
Institutions
- Ulsan College (KR)
- Gachon University (KR)
- Asan Medical Center (KR)
- University of Ulsan (KR)
- Gachon University Gil Medical Center (KR)
- National Cancer Center (US)
- Daewon Pharm (South Korea) (KR)
- National Cancer Center (KR)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Incheon Medical Center (KR)
- Hanyang University (KR)
- Catholic University of Korea (KR)
Publication Details
- Journal
- Advances in Radiation Oncology
- Published
- 2025-10-30
- DOI
- https://doi.org/10.1016/j.adro.2025.101947
- Citations
- 1
- Primary Topic
- Boron Compounds in Chemistry
- Type
- article
- Field-Weighted Citation Impact
- 1.36
Funders
- Ministry of Trade, Industry and Energy